Biocon Limited - Product Pipeline Review - 2016

  • ID: 3960441
  • Company Profile
  • 51 pages
  • Global Markets Direct
  • Biocon
1 of 5
Biocon Limited - Product Pipeline Review - 2016

The report ‘Biocon Limited - Product Pipeline Review - 2016’, provides an overview of the Biocon Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Biocon Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note - : Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

- The report provides a snapshot of the pipeline therapeutic landscape of Biocon Limited
- The report provides overview of Biocon Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Biocon Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Biocon Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to Buy:

- Evaluate Biocon Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Biocon Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Biocon Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5
Introduction

Biocon Limited Snapshot

Biocon Limited Overview

Key Facts

Biocon Limited - Research and Development Overview

Key Therapeutic Areas

Biocon Limited - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Partnered Products

Partnered Products/Combination Treatment Modalities

Biocon Limited - Pipeline Products Glance

Biocon Limited - Late Stage Pipeline Products

Pre-Registration Products/Combination Treatment Modalities

Phase III Products/Combination Treatment Modalities

Biocon Limited - Clinical Stage Pipeline Products

Phase II Products/Combination Treatment Modalities

Phase I Products/Combination Treatment Modalities

Biocon Limited - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Biocon Limited - Drug Profiles

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bevacizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BVX-20 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

insulin aspart - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

insulin glargine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

insulin human - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

insulin lispro - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

insulin tregopil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody Conjugates for Oncology and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pegfilgrastim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trastuzumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biocon Limited - Pipeline Analysis

Biocon Limited - Pipeline Products by Target

Biocon Limited - Pipeline Products by Route of Administration

Biocon Limited - Pipeline Products by Molecule Type

Biocon Limited - Pipeline Products by Mechanism of Action

Biocon Limited - Dormant Projects

Biocon Limited - Company Statement

Biocon Limited - Locations And Subsidiaries

Head Office

Other Locations & Subsidiaries

List of Tables

Biocon Limited, Key Facts

Biocon Limited - Pipeline by Indication, 2016

Biocon Limited - Pipeline by Stage of Development, 2016

Biocon Limited - Monotherapy Products in Pipeline, 2016

Biocon Limited - Partnered Products in Pipeline, 2016

Biocon Limited - Partnered Products/ Combination Treatment Modalities, 2016

Biocon Limited - Pre-Registration, 2016

Biocon Limited - Phase III, 2016

Biocon Limited - Phase II, 2016

Biocon Limited - Phase I, 2016

Biocon Limited - Preclinical, 2016

Biocon Limited - Pipeline by Target, 2016

Biocon Limited - Pipeline by Route of Administration, 2016

Biocon Limited - Pipeline by Molecule Type, 2016

Biocon Limited - Pipeline Products by Mechanism of Action, 2016

Biocon Limited - Dormant Developmental Projects,2016

Biocon Limited, Other Locations

Biocon Limited, Subsidiaries

List of Figures

Biocon Limited - Pipeline by Top 10 Indication, 2016

Biocon Limited - Pipeline by Stage of Development, 2016

Biocon Limited - Monotherapy Products in Pipeline, 2016

Biocon Limited - Partnered Products in Pipeline, 2016

Biocon Limited - Pipeline by Target, 2016

Biocon Limited - Pipeline by Route of Administration, 2016

Biocon Limited - Pipeline by Molecule Type, 2016

Biocon Limited - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- Bristol-Myers Squibb Company
- ChemoCentryx, Inc.
- Ligand Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll